Movement Alert｜Natera Intraday Rise 3.13% in Regular Trading, Price Target Hikes and Product Progress Reinforce Valuation Expectations

Market Focus10-21

On October 21, Natera rose 3.13% in Regular Trading, trading near $418.02 per share, with turnover of $52.96 million.

The move was accompanied by recent analyst price-target increases and continued product and regulatory progress, which strengthened market expectations for further valuation re-rating in the genetic testing space.

Recent updates show Morgan Stanley raised its target price to $435 from $355 while maintaining an Overweight rating, following other bullish revisions including RBC to $460 and UBS to $435. At the product level, Natera said its multi-cancer early detection assay received FDA Breakthrough Device Designation, and Signatera won approval in Japan as a companion diagnostic for muscle-invasive bladder cancer. Fundamentally, the company reported second-quarter revenue of $752.8 million, up 37.7% year over year, and raised full-year revenue guidance to $2.85 billion to $2.91 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment